2/25
11:29 am
amgn
Is Amgen Stock Outperforming the Dow? [Yahoo! Finance]
Low
Report
Is Amgen Stock Outperforming the Dow? [Yahoo! Finance]
2/24
04:01 pm
amgn
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
Low
Report
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
2/21
06:31 am
amgn
Amgen (NASDAQ:AMGN) was upgraded by analysts at Barclays PLC to a "hold" rating.
Low
Report
Amgen (NASDAQ:AMGN) was upgraded by analysts at Barclays PLC to a "hold" rating.
2/20
10:12 am
amgn
Amgen (NASDAQ:AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $350.00 price target on the stock.
Low
Report
Amgen (NASDAQ:AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $350.00 price target on the stock.
2/19
09:01 pm
amgn
Amgen (NASDAQ:AMGN) was given a new $185.00 price target on by analysts at Barclays PLC.
Low
Report
Amgen (NASDAQ:AMGN) was given a new $185.00 price target on by analysts at Barclays PLC.
2/19
08:02 am
amgn
Amgen (NASDAQ:AMGN) was given a new $375.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Amgen (NASDAQ:AMGN) was given a new $375.00 price target on by analysts at Wells Fargo & Company.
2/18
09:17 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Rothschild & Co Redburn from $180.00 to $200.00. They now have a "sell" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Rothschild & Co Redburn from $180.00 to $200.00. They now have a "sell" rating on the stock.
2/18
07:18 am
amgn
Amgen (NASDAQ:AMGN) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Amgen (NASDAQ:AMGN) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/16
05:31 pm
amgn
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
Low
Report
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
2/16
05:31 pm
amgn
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
Low
Report
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
2/14
06:24 am
amgn
Amgen (NASDAQ:AMGN) was downgraded by analysts at Freedom Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Amgen (NASDAQ:AMGN) was downgraded by analysts at Freedom Capital from a "strong-buy" rating to a "hold" rating.
2/13
04:01 pm
amgn
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
Low
Report
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
2/12
02:23 pm
amgn
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 [Yahoo! Finance]
Low
Report
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 [Yahoo! Finance]
2/12
09:00 am
amgn
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
Low
Report
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
2/11
09:17 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Mizuho from $280.00 to $295.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Mizuho from $280.00 to $295.00. They now have an "outperform" rating on the stock.
2/10
09:18 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Daiwa Securities Group Inc. from $370.00 to $410.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Daiwa Securities Group Inc. from $370.00 to $410.00. They now have an "outperform" rating on the stock.
2/10
08:39 am
amgn
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend [Yahoo! Finance]
Low
Report
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend [Yahoo! Finance]
2/6
12:44 pm
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.
2/6
09:47 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.
2/6
09:17 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.
2/5
12:51 pm
amgn
CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]
Low
Report
CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]
2/4
03:42 pm
amgn
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
Low
Report
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
2/4
02:48 pm
amgn
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance]
Low
Report
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance]
2/4
11:36 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.
Low
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.
2/4
09:16 am
amgn
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.
Medium
Report
Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.